Iovance Biotherapeutics recently announced plans to launch a single-arm registration clinical trial in the second quarter of 2026.

The trial will target patients with advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS) after second-line treatment. The design of this single-arm trial aims to accelerate the registration process for the therapy. The company's decision to focus on these two rare soft tissue sarcoma subtypes reflects its strategic positioning in the field of tumor immunotherapy. By targeting advanced patient populations who have undergone first-line treatment, Iovance hopes to open new avenues for the application of its cell therapy in these hard-to-treat cancers. The timing of the trial is based on a comprehensive assessment of the company's R&D pipeline progress. The choice of the second quarter of 2026 takes into account both the maturity of preclinical research and the time required for regulatory communications. The adoption of a single-arm trial design is expected to accelerate the accessibility of potential therapies while ensuring scientific rigor.